CLN-619
Phase 1Small molecule
CLN-619 is one of 83 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
311 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Paraplatin
AAvyxa
Phase 2
Tecentriq
RochePhase 2
Taxotere
AAvyxa
Phase 2
Yervoy
Bristol-Myers SquibbPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Erbitux
IImclone
Phase 2
Braftovi
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CLN-619. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCullinan Therapeutics Inc.